ReviewApoptosis : an international journal on programmed cell death2025
Manipulating the PANoptosome: baseless hype or a newfound hope for human immunity?
Review in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Harnessing machine learning-driven multiomics integration: deciphering programmed cell death networks for prognostication and immunotherapy prediction in lung adenocarcinoma.Cell biology and toxicology · 2026Article
- Recent advances in PANoptosis research in kidney disease: mechanistic networks, pathological roles, and potential intervention strategies.Frontiers in immunology · 2026Review
- PANoptosis-related genes in rheumatoid arthritis synovial tissue: screening, validation, and functional implications.Frontiers in immunology · 2026Article
- cGAS-STING and PANoptosis: Interplay, Underlying Mechanisms, and Therapeutic Targets.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human immune system uses many tactics to protect itself from harm, attempting to restore homeostatic conditions. Of these tactics, the primary defense mechanism which is activated is innate immunity. Innate immunity employs phagocytic cells which contain Pattern Recognition Receptors (PRRs) on their surface to promote attachment to certain molecules on pathogens and/or generally damaged/injured cells, which contain Pattern-Associated Molecular Patterns (PAMPs) and Damage/Danger-Associated Molecular Patterns (DAMPs), respectively. DAMPs and PAMPs associate with PRRs in host cells. The interaction between innate immune cells and pathogenic molecular patterns triggers programmed cell death (PCD) pathways; the three main ones being pyroptosis, apoptosis, and necroptosis. Historically, the three were thought to operate autonomously, with no intersection between any, but emerging research has brought a new concept into the limelight: PANoptosis. PANoptosis is now recognized as a distinct, innate immune-regulated inflammatory cell death pathway orchestrated by the PANoptosome, a multiprotein complex that integrates molecular components from pyroptosis, apoptosis, and necroptosis, yet functions independently of them. This integrated pathway plays a crucial role in eliminating infected or damaged cells and modulating immune responses. PANoptosis must be tightly regulated at all times, as any abnormality may increase the chances of a multitude of chronic, severe, and potentially terminal illnesses. Developing a better understanding of PANoptosis offers a promising set of possibilities within immunology research and medicine. By elucidating the relationship between the PCD pathways and how they come together to form a PANoptosome, better targets for treatment can be isolated and integrated into new innovative treatments for a wide range of ailments. This review addresses the mechanisms surrounding PANoptosis and its possible implications for the future of medicine, carrying the potential to bridge the gap of knowledge that exists surrounding complex immunological illnesses and also identifying new markers and significant factors contributing to a treatment/cure.
Indexed as
Identifiers
40702246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.